Last €59.32 EUR
Change Today -0.33 / -0.55%
Volume 100.0
As of 3:18 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/26/15 - €60.89
52 Week Low
02/13/14 - €43.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CSL LTD (CSJ)

Related News

No related news articles were found.

csl ltd (CSJ) Related Businessweek News

View More BusinessWeek News

csl ltd (CSJ) Details

CSL Limited is engaged in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including vaccines to protect against viral and bacterial diseases; pharmaceuticals to treat a range of human medical conditions; diagnostic products to determine compatibility of donor-recipient blood in transfusion settings; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment is engaged in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

12,196 Employees
Last Reported Date: 08/12/14
Founded in 1916

csl ltd (CSJ) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $3.1M
Chief Financial Officer
Total Annual Compensation: $1.6M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Manufacturing Ope...
Total Annual Compensation: $1.1M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $998.2K
Compensation as of Fiscal Year 2014.

csl ltd (CSJ) Key Developments

CSL Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM

CSL Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Paul R. Perreault, Chief Executive Officer, Managing Director, Executive Director and Member of Innovation & Development Committee.

CCL Limited Announces New EUR 350 Million Private Placement in the U.S

CSL Limited announced that on 12 November 2014 it closed a new EUR 350 million private placement in the U.S. The private placement was foreshadowed in CSL's full year announcement in August 2014. The private placement consists of three maturities as: 8-year bullet 10-year bullet 12-year bullet; amount EUR 100 million EUR 150 million EUR 100 million; coupon 1.65% 1.93% 2.10%. The private placement has a weighted average interest rate of 1.90% and an average life of 10 years.

CSL Ltd. Launches AEGIS-I, a Phase 2b Clinical Study of CSL112

CSL Ltd. announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I). Administered as a short series of weekly infusions, CSL112 is designed to rapidly remove cholesterol from the arteries and stabilize lesions at risk of rupture. This represents a new approach to reduce the high incidence of early recurrent cardiovascular events in the days and weeks following a heart attack. AEGIS-I is a Phase 2b, global, randomized, placebo-controlled, dose-ranging study investigating the safety and tolerability of multiple dose administration of CSL112 in 1,200 patients who experienced an acute myocardial infarction or heart attack. Secondary outcome measures include time-to-first occurrence of a major adverse cardiovascular event (MACE) defined as cardiovascular death, myocardial infarction (MI), ischemic stroke and hospitalization for unstable angina. Results of the study are expected in 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSJ:GR €59.32 EUR -0.33

CSJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,792 JPY +24.50
Biocon Ltd 413.10 INR 0.00
Green Cross Corp/South Korea 135,500 KRW -2,000.00
Grifols SA €36.63 EUR +1.02
Shire PLC 4,868 GBp +52.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CSJ Industry Range
Price/Earnings 25.1x
Price/Sales 6.1x
Price/Book 10.1x
Price/Cash Flow 24.5x
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at